CAS 106308-44-5|Rufinamide
| Common Name | Rufinamide | ||
|---|---|---|---|
| CAS Number | 106308-44-5 | Molecular Weight | 238.193 |
| Density | 1.5±0.1 g/cm3 | Boiling Point | 473.8±55.0 °C at 760 mmHg |
| Molecular Formula | C10H8F2N4O | Melting Point | 232-234?C |
| MSDS | ChineseUSA | Flash Point | 240.4±31.5 °C |
Names
| Name | Rufinamide |
|---|---|
| Synonym | More Synonyms |
Rufinamide BiologicalActivity
| Description | Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).IC50 Value:Target: in vitro:in vivo: Rufinamide and amitriptyline alleviated injury-induced mechanical allodynia for 4 h (maximal effect: 0.10 ± 0.03 g (mean ± SD) to 1.99 ± 0.26 g for rufinamide and 0.25 ± 0.22 g to 1.92 ± 0.85 g for amitriptyline) in mice [1]. Oral rufinamide suppressed pentylenetetrazol-induced seizures in mice (ED(50) 45.8 mg/kg) but not rats, and was active against MES-induced tonic seizures in mice (ED(50) 23.9 mg/kg) and rats (ED(50) 6.1 mg/kg) [2]. Intraperitoneal rufinamide suppressed pentylenetetrazol-, bicuculline-, and picrotoxin-induced clonus in mice (ED(50) 54.0, 50.5, and 76.3 mg/kg, respectively).Clinical trial: Exploratory Study to Evaluate the Effect of SYN-111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD). Phase 2 |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>OthersNatural Products >>AlkaloidResearch Areas >>Neurological Disease |
| References | [1]. Suter MR, Kirschmann G, Laedermann CJ, Rufinamide attenuates mechanical allodynia in a model of neuropathic pain in the mouse and stabilizes voltage-gated sodium channel inactivated state. Anesthesiology. 2013 Jan;118(1):160-72. [2]. White HS, Franklin MR, Kupferberg HJ, The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models. Epilepsia. 2008 Jul;49(7):1213-20. |
Chemical & Physical Properties
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 473.8±55.0 °C at 760 mmHg |
| Melting Point | 232-234?C |
| Molecular Formula | C10H8F2N4O |
| Molecular Weight | 238.193 |
| Flash Point | 240.4±31.5 °C |
| Exact Mass | 238.066620 |
| PSA | 73.80000 |
| LogP | 0.05 |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.635 |
| InChIKey | POGQSBRIGCQNEG-UHFFFAOYSA-N |
| SMILES | NC(=O)c1cn(Cc2c(F)cccc2F)nn1 |
| Storage condition | −20°C |
| Water Solubility | DMSO: soluble9mg/mL |
Safety Information
| Hazard Codes | F,T |
|---|---|
| Risk Phrases | 11-23/24/25-39/23/24/25-48-41-38-28 |
| Safety Phrases | 7-16-36/37-45-36/37/39-28-26-24/25 |
| RIDADR | UN 1648 3 / PGII |
Articles39
More Articles| Dose-dependent pharmacokinetics and brain penetration of rufinamide following intravenous and oral administration to rats. Eur. J. Pharm. Sci. 68 , 106-13, (2015) Rufinamide is a third-generation antiepileptic drug, approved recently as an orphan drug for the treatment of Lennox-Gastaut syndrome. Although extensive research was conducted, its pharmacokinetics i... | |
| Toxicological screening of human plasma by on-line SPE-HPLC-DAD: identification and quantification of basic drugs and metabolites. Biomed. Chromatogr. 29 , 935-52, (2015) An automated multi-analyte screening method for the identification and quantification of 92 drugs and metabolites based on on-line solid-phase extraction-high-performance liquid chromatography-diode a... | |
| Rufinamide for the treatment of Lennox-Gastaut syndrome. Expert Opin. Pharmacother. 12(5) , 801-6, (2011) Lennox-Gastaut syndrome (LGS) is a severe treatment-resistant childhood-onset epilepsy. This review examines the role of the new drug rufinamide for the treatment of LGS.MEDLINE and Google Scholar sea... |
Synonyms
| 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide |
| 1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
| Rufinamide |
| 1H-1,2,3-Triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]- |
| 1-((2,6-Difluorophenyl)methyl)-1H-1,2,3-triazole-4-carboxamide |
| Banzel |
| Inovelon |
